Cargando…
Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia
Sudden cardiac death due to arrhythmias, such as atrial fibrillation or ventricular tachycardia, account for 15–20% of all deaths. Myocardial infarction increases the burden of atrial fibrillation and ventricular tachycardia by structural and electrical remodeling of the heart. The current managemen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604396/ https://www.ncbi.nlm.nih.gov/pubmed/36293490 http://dx.doi.org/10.3390/ijms232012612 |
_version_ | 1784817803611602944 |
---|---|
author | Mircea, Andrei Alexandru Rusu, Mihaela Liehn, Elisa Anamaria Bucur, Octavian |
author_facet | Mircea, Andrei Alexandru Rusu, Mihaela Liehn, Elisa Anamaria Bucur, Octavian |
author_sort | Mircea, Andrei Alexandru |
collection | PubMed |
description | Sudden cardiac death due to arrhythmias, such as atrial fibrillation or ventricular tachycardia, account for 15–20% of all deaths. Myocardial infarction increases the burden of atrial fibrillation and ventricular tachycardia by structural and electrical remodeling of the heart. The current management of new-onset atrial fibrillation includes electric cardioversion with very high conversion rates and pharmacologic cardioversion, with less a than 50% conversion rate. If atrial fibrillation cannot be converted, the focus becomes the control of the symptoms ensuring a constant rhythm and rate control, without considering other contributory factors such as autonomic imbalance. Recently, a huge success was obtained by developing ablation techniques or addressing the vagal nerve stimulation. On the other hand, ventricular tachycardia is more sensitive to drug therapies. However, in cases of non-responsiveness to drugs, the usual therapeutic choice is represented by stereotactic ablative therapy or catheter ablation. This review focuses on these newly developed strategies for treatment of arrhythmias in clinical practice, specifically on vernakalant and low-level tragus stimulation for atrial fibrillation and stereotactic ablative therapy for drug-refractory ventricular tachycardia. These therapies are important for the significant improvement of the management of atrial fibrillation and ventricular tachycardia, providing: (1) a safer profile than current therapies, (2) higher success rate than current solutions, (3) low cost of delivery. |
format | Online Article Text |
id | pubmed-9604396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96043962022-10-27 Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia Mircea, Andrei Alexandru Rusu, Mihaela Liehn, Elisa Anamaria Bucur, Octavian Int J Mol Sci Review Sudden cardiac death due to arrhythmias, such as atrial fibrillation or ventricular tachycardia, account for 15–20% of all deaths. Myocardial infarction increases the burden of atrial fibrillation and ventricular tachycardia by structural and electrical remodeling of the heart. The current management of new-onset atrial fibrillation includes electric cardioversion with very high conversion rates and pharmacologic cardioversion, with less a than 50% conversion rate. If atrial fibrillation cannot be converted, the focus becomes the control of the symptoms ensuring a constant rhythm and rate control, without considering other contributory factors such as autonomic imbalance. Recently, a huge success was obtained by developing ablation techniques or addressing the vagal nerve stimulation. On the other hand, ventricular tachycardia is more sensitive to drug therapies. However, in cases of non-responsiveness to drugs, the usual therapeutic choice is represented by stereotactic ablative therapy or catheter ablation. This review focuses on these newly developed strategies for treatment of arrhythmias in clinical practice, specifically on vernakalant and low-level tragus stimulation for atrial fibrillation and stereotactic ablative therapy for drug-refractory ventricular tachycardia. These therapies are important for the significant improvement of the management of atrial fibrillation and ventricular tachycardia, providing: (1) a safer profile than current therapies, (2) higher success rate than current solutions, (3) low cost of delivery. MDPI 2022-10-20 /pmc/articles/PMC9604396/ /pubmed/36293490 http://dx.doi.org/10.3390/ijms232012612 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mircea, Andrei Alexandru Rusu, Mihaela Liehn, Elisa Anamaria Bucur, Octavian Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia |
title | Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia |
title_full | Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia |
title_fullStr | Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia |
title_full_unstemmed | Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia |
title_short | Promising Therapies for Atrial Fibrillation and Ventricular Tachycardia |
title_sort | promising therapies for atrial fibrillation and ventricular tachycardia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604396/ https://www.ncbi.nlm.nih.gov/pubmed/36293490 http://dx.doi.org/10.3390/ijms232012612 |
work_keys_str_mv | AT mirceaandreialexandru promisingtherapiesforatrialfibrillationandventriculartachycardia AT rusumihaela promisingtherapiesforatrialfibrillationandventriculartachycardia AT liehnelisaanamaria promisingtherapiesforatrialfibrillationandventriculartachycardia AT bucuroctavian promisingtherapiesforatrialfibrillationandventriculartachycardia |